Congenital Fibrinogen Deficiency in India and Role of Human Fibrinogen Concentrate.
Congenital fibrinogen deficiency
Cryoprecipitate
Dysfibrinogenemia
Fresh frozen plasma
Human fibrinogen concentrate
Hypofibrinogenemia
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
02
2021
accepted:
25
03
2021
pubmed:
7
6
2021
medline:
15
12
2021
entrez:
6
6
2021
Statut:
ppublish
Résumé
Congenital fibrinogen deficiency is an inherited disorder due to genetic mutations with diverse presentations arising from reduced fibrinogen levels (hypofibrinogenemia), absence of fibrinogen in circulation (afibrinogenemia), abnormal functioning (dysfibrinogenemia) or both reduced levels and abnormal functioning (hypodysfibrinogenemia) of fibrinogen. The decreased fibrinogen concentration in congenital fibrinogen deficiency necessitates fibrinogen replacement therapy with fresh frozen plasma, cryoprecipitate, or human fibrinogen concentrate. However, the use of fresh frozen plasma and cryoprecipitate is limited owing to their longer transfusion time, requirement of high doses, volume overload, risk of viral transmission, and other safety concerns. The availability of human fibrinogen concentrate has made it the preferred replacement alternative due to its reduced risk of viral transmission, smaller infusion volume, and accurate dosing. The hemostatic efficacy and safety of human fibrinogen concentrate in congenital fibrinogen deficiency is well established in the literature. We review the prevalence of congenital fibrinogen deficiency in India and the current role of human fibrinogen concentrate in its management.
Identifiants
pubmed: 34091452
pii: 000516339
doi: 10.1159/000516339
doi:
Substances chimiques
Fibrinogen
9001-32-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-602Informations de copyright
© 2021 S. Karger AG, Basel.